APGE Apogee Therapeutics, Inc.
APGE Apogee Therapeutics, Inc.
Healthcare · Biotechnology
No longer tracked since 2026-09-04 — left the market.
Market read
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Decision history
1 scored call · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Apogee Therapeutics furnished its earnings release to the SEC on August 10, 2026 (8-K, Item 2.02) and filed its 10-Q for the quarter ended June 30, 2026 the same day. No figures from these filings are recorded here.
full note →Against street estimates
How APGE's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
APGE research tape
48 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.